Limits...
Modulator of apoptosis 1 (MOAP-1) is a tumor suppressor protein linked to the RASSF1A protein.

Law J, Salla M, Zare A, Wong Y, Luong L, Volodko N, Svystun O, Flood K, Lim J, Sung M, Dyck JR, Tan CT, Su YC, Yu VC, Mackey J, Baksh S - J. Biol. Chem. (2015)

Bottom Line: It is an integral partner to the tumor suppressor protein, Ras association domain family 1A (RASSF1A), and functions to activate the Bcl-2 family pro-apoptotic protein Bax.Although RASSF1A is now considered a bona fide tumor suppressor protein, the role of MOAP-1 as a tumor suppressor protein has yet to be determined.Overexpression of MOAP-1 in several cancer cell lines resulted in reduced tumorigenesis and up-regulation of genes involved in cancer regulatory pathways that include apoptosis (p53, Fas, and MST1), DNA damage control (poly(ADP)-ribose polymerase and ataxia telangiectasia mutated), those within the cell metabolism (IR-α, IR-β, and AMP-activated protein kinase), and a stabilizing effect on microtubules.

View Article: PubMed Central - PubMed

Affiliation: From the Departments of Biochemistry and.

Show MeSH

Related in: MedlinePlus

Evidence of reduced MOAP-1 expression from cancer databases and in neuroblastoma.A, differential expression analysis of MOAP-1 in normal versus cancer tissues from the microarray database Oncomine. Results from individual microarray studies are each represented by a single point on this plot (n = 48 within each study). The y axis depicts the fold-change in MOAP-1 mRNA levels relative to normal tissue for each of the multiple cancer types for which MOAP-1 expression data were available, as shown on the x axis. Horizontal bars represent the average MOAP-1 mRNA fold-change within that cancer type. All fold-changes are greater than or equal to 1.5, and p values are less than or equal to 0.05. B and C, Kaplan-Meier survival curves for neuroblastoma patients demonstrating a correlation between expression levels of MOAP-1 (n high expression = 72; n low expression = 16; expression cutoff, 700.1 for high expression versus low expression for MOAP-1 (arbitrary mRNA units indicated)) (B) and RASSF1A (n high expression = 61; n low expression = 27; expression cutoff, 101.7 (same comparison as for MOAP-1)) with overall patient survival probability from neuroblastoma (C). D, mRNA expression of MOAP-1 by qPCR 1 in normal (normal human bronchoepithelial, breast, and colon epithelial cells data were pooled) versus neuroblastoma cell lines (Be(2)c, GoTo, LAN-1, KAN, Nub7, SKNAS, and SH-SY5Y). E, protein expression of MOAP-1 in neuroblastoma cell lines as indicated. IB, immunoblot.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4591801&req=5

Figure 1: Evidence of reduced MOAP-1 expression from cancer databases and in neuroblastoma.A, differential expression analysis of MOAP-1 in normal versus cancer tissues from the microarray database Oncomine. Results from individual microarray studies are each represented by a single point on this plot (n = 48 within each study). The y axis depicts the fold-change in MOAP-1 mRNA levels relative to normal tissue for each of the multiple cancer types for which MOAP-1 expression data were available, as shown on the x axis. Horizontal bars represent the average MOAP-1 mRNA fold-change within that cancer type. All fold-changes are greater than or equal to 1.5, and p values are less than or equal to 0.05. B and C, Kaplan-Meier survival curves for neuroblastoma patients demonstrating a correlation between expression levels of MOAP-1 (n high expression = 72; n low expression = 16; expression cutoff, 700.1 for high expression versus low expression for MOAP-1 (arbitrary mRNA units indicated)) (B) and RASSF1A (n high expression = 61; n low expression = 27; expression cutoff, 101.7 (same comparison as for MOAP-1)) with overall patient survival probability from neuroblastoma (C). D, mRNA expression of MOAP-1 by qPCR 1 in normal (normal human bronchoepithelial, breast, and colon epithelial cells data were pooled) versus neuroblastoma cell lines (Be(2)c, GoTo, LAN-1, KAN, Nub7, SKNAS, and SH-SY5Y). E, protein expression of MOAP-1 in neuroblastoma cell lines as indicated. IB, immunoblot.

Mentions: A meta-analysis of microarray data was performed using the on-line cancer microarray database Oncomine (Compendia Bioscience, Ann Arbor, MI) (15). Differential expression analysis of MOAP-1 was carried out in samples from normal versus malignant tissues with data subsequently compiled from microarray studies meeting the threshold fold-change ≥1.5 and p value ≤ 0.05. The results obtained from this meta-analysis indicate that MOAP-1 expression is markedly reduced in multiple types of human cancers (Fig. 1A), especially in the brain, breast, blood, skin, and lung suggesting that loss of MOAP-1 is important for tumorigenesis to occur. MOAP-1 may possess a potential tumor suppressor function in specific cell types. Interestingly, parathyroid, myeloma, prostate/ovarian/cervical (that is the reproductive organs), and gastric datasets revealed elevated expression of MOAP-1 to suggest that MOAP-1 expression can vary widely and may have differential function in numerous tissues. Please note that plots for “sarcoma” classification include the following: dedifferentiated liposarcoma, myxofibrosarcoma, round cell liposarcoma, and fibrosarcoma. The “leukemia” plots include B-cell childhood acute lymphoblastic leukemia, T-cell prolymphocytic leukemia (all underexpressed), and Hairy cell leukemia (overexpressed). The “lymphoma” plots include anaplastic large cell lymphoma (ALK-positive), primary cutaneous anaplastic large cell lymphoma, classical Hodgkin lymphoma, angioimmunoblastic T-cell lymphoma (all underexpressed), and mantle cell lymphoma (overexpressed).


Modulator of apoptosis 1 (MOAP-1) is a tumor suppressor protein linked to the RASSF1A protein.

Law J, Salla M, Zare A, Wong Y, Luong L, Volodko N, Svystun O, Flood K, Lim J, Sung M, Dyck JR, Tan CT, Su YC, Yu VC, Mackey J, Baksh S - J. Biol. Chem. (2015)

Evidence of reduced MOAP-1 expression from cancer databases and in neuroblastoma.A, differential expression analysis of MOAP-1 in normal versus cancer tissues from the microarray database Oncomine. Results from individual microarray studies are each represented by a single point on this plot (n = 48 within each study). The y axis depicts the fold-change in MOAP-1 mRNA levels relative to normal tissue for each of the multiple cancer types for which MOAP-1 expression data were available, as shown on the x axis. Horizontal bars represent the average MOAP-1 mRNA fold-change within that cancer type. All fold-changes are greater than or equal to 1.5, and p values are less than or equal to 0.05. B and C, Kaplan-Meier survival curves for neuroblastoma patients demonstrating a correlation between expression levels of MOAP-1 (n high expression = 72; n low expression = 16; expression cutoff, 700.1 for high expression versus low expression for MOAP-1 (arbitrary mRNA units indicated)) (B) and RASSF1A (n high expression = 61; n low expression = 27; expression cutoff, 101.7 (same comparison as for MOAP-1)) with overall patient survival probability from neuroblastoma (C). D, mRNA expression of MOAP-1 by qPCR 1 in normal (normal human bronchoepithelial, breast, and colon epithelial cells data were pooled) versus neuroblastoma cell lines (Be(2)c, GoTo, LAN-1, KAN, Nub7, SKNAS, and SH-SY5Y). E, protein expression of MOAP-1 in neuroblastoma cell lines as indicated. IB, immunoblot.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4591801&req=5

Figure 1: Evidence of reduced MOAP-1 expression from cancer databases and in neuroblastoma.A, differential expression analysis of MOAP-1 in normal versus cancer tissues from the microarray database Oncomine. Results from individual microarray studies are each represented by a single point on this plot (n = 48 within each study). The y axis depicts the fold-change in MOAP-1 mRNA levels relative to normal tissue for each of the multiple cancer types for which MOAP-1 expression data were available, as shown on the x axis. Horizontal bars represent the average MOAP-1 mRNA fold-change within that cancer type. All fold-changes are greater than or equal to 1.5, and p values are less than or equal to 0.05. B and C, Kaplan-Meier survival curves for neuroblastoma patients demonstrating a correlation between expression levels of MOAP-1 (n high expression = 72; n low expression = 16; expression cutoff, 700.1 for high expression versus low expression for MOAP-1 (arbitrary mRNA units indicated)) (B) and RASSF1A (n high expression = 61; n low expression = 27; expression cutoff, 101.7 (same comparison as for MOAP-1)) with overall patient survival probability from neuroblastoma (C). D, mRNA expression of MOAP-1 by qPCR 1 in normal (normal human bronchoepithelial, breast, and colon epithelial cells data were pooled) versus neuroblastoma cell lines (Be(2)c, GoTo, LAN-1, KAN, Nub7, SKNAS, and SH-SY5Y). E, protein expression of MOAP-1 in neuroblastoma cell lines as indicated. IB, immunoblot.
Mentions: A meta-analysis of microarray data was performed using the on-line cancer microarray database Oncomine (Compendia Bioscience, Ann Arbor, MI) (15). Differential expression analysis of MOAP-1 was carried out in samples from normal versus malignant tissues with data subsequently compiled from microarray studies meeting the threshold fold-change ≥1.5 and p value ≤ 0.05. The results obtained from this meta-analysis indicate that MOAP-1 expression is markedly reduced in multiple types of human cancers (Fig. 1A), especially in the brain, breast, blood, skin, and lung suggesting that loss of MOAP-1 is important for tumorigenesis to occur. MOAP-1 may possess a potential tumor suppressor function in specific cell types. Interestingly, parathyroid, myeloma, prostate/ovarian/cervical (that is the reproductive organs), and gastric datasets revealed elevated expression of MOAP-1 to suggest that MOAP-1 expression can vary widely and may have differential function in numerous tissues. Please note that plots for “sarcoma” classification include the following: dedifferentiated liposarcoma, myxofibrosarcoma, round cell liposarcoma, and fibrosarcoma. The “leukemia” plots include B-cell childhood acute lymphoblastic leukemia, T-cell prolymphocytic leukemia (all underexpressed), and Hairy cell leukemia (overexpressed). The “lymphoma” plots include anaplastic large cell lymphoma (ALK-positive), primary cutaneous anaplastic large cell lymphoma, classical Hodgkin lymphoma, angioimmunoblastic T-cell lymphoma (all underexpressed), and mantle cell lymphoma (overexpressed).

Bottom Line: It is an integral partner to the tumor suppressor protein, Ras association domain family 1A (RASSF1A), and functions to activate the Bcl-2 family pro-apoptotic protein Bax.Although RASSF1A is now considered a bona fide tumor suppressor protein, the role of MOAP-1 as a tumor suppressor protein has yet to be determined.Overexpression of MOAP-1 in several cancer cell lines resulted in reduced tumorigenesis and up-regulation of genes involved in cancer regulatory pathways that include apoptosis (p53, Fas, and MST1), DNA damage control (poly(ADP)-ribose polymerase and ataxia telangiectasia mutated), those within the cell metabolism (IR-α, IR-β, and AMP-activated protein kinase), and a stabilizing effect on microtubules.

View Article: PubMed Central - PubMed

Affiliation: From the Departments of Biochemistry and.

Show MeSH
Related in: MedlinePlus